These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4459505)

  • 41. [Evaluation of rubella vaccine (HPV 77, DK 12) in Mexico City. Possible transmission of its viral strain].
    Ruíz-Gomez J; Gutiérrez G; Velasco-Cándano LR
    Arch Invest Med (Mex); 1971; 2(2):95-102. PubMed ID: 5136438
    [No Abstract]   [Full Text] [Related]  

  • 42. [Evaluation of rubella vaccine (HPV 77, DK12) in Mexico City. (Possible transmission of the vaccine strain)].
    Ruíz-Gomez J; Gutiérrez G; Velasco-Cándano LR
    Arch Invest Med (Mex); 1971; 2(2):95-102. PubMed ID: 5116025
    [No Abstract]   [Full Text] [Related]  

  • 43. [Clinical test of an anti-rubella vaccine on a group of children belonging to a closed community].
    Gasparini V; Trivello R; Diana L; Romano M; Drago E; Rausa G
    Minerva Med; 1970 Apr; 61(30 Suppl):1583-9. PubMed ID: 5439723
    [No Abstract]   [Full Text] [Related]  

  • 44. Persistence of antibody 10 years after vaccination with Wistar RA27/3 strain live attenuated rubella vaccine.
    Hillary IB; Griffith AH
    Br Med J; 1980 Jun; 280(6231):1580-1. PubMed ID: 7427177
    [No Abstract]   [Full Text] [Related]  

  • 45. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine.
    Hillary IB; Griffith AH
    Vaccine; 1984 Dec; 2(4):274-6. PubMed ID: 6531967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attenuated rubella virus. II. Production of an experimental live-virus vaccine and clinical trial.
    Meyer HM; Parkman PD; Panos TC
    N Engl J Med; 1966 Sep; 275(11):575-80. PubMed ID: 5331945
    [No Abstract]   [Full Text] [Related]  

  • 47. Rubella antibody screening.
    Lang DJ
    J Fam Pract; 1978 Oct; 7(4):676-8. PubMed ID: 702068
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers.
    Shokri S; Shahkarami MK; Shafyi A; Mohammadi A; Esna-Ashari F; Hamta A
    J Virol Methods; 2019 Feb; 264():18-22. PubMed ID: 30144493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of attenuated rubella virus vaccines in Japan.
    Shishido A; Ohtawara M
    Jpn J Med Sci Biol; 1976 Oct; 29(5):227-53. PubMed ID: 827627
    [No Abstract]   [Full Text] [Related]  

  • 50. [Variation of antibody titers following rubella immunization].
    Sawada K; Sunaga H
    Nihon Eiseigaku Zasshi; 1975 Apr; 30(1):223. PubMed ID: 1169551
    [No Abstract]   [Full Text] [Related]  

  • 51. Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27/3 strains.
    Gershon AA; Frey HM; Borkowsky W; Steinberg S
    Am J Med Sci; 1980; 279(2):95-7. PubMed ID: 7386521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of rubella vaccination.
    Freestone DS
    Br Med J; 1978 Sep; 2(6138):697-8. PubMed ID: 698669
    [No Abstract]   [Full Text] [Related]  

  • 53. Field work of rubella attenuated live virus vaccine in Thailand.
    Supawadee J; Suprasert S; Suzuki H; Yamazi Y; Takeuchi Y
    Nihon Ika Daigaku Zasshi; 1991 Jun; 58(3):350-2. PubMed ID: 1880203
    [No Abstract]   [Full Text] [Related]  

  • 54. Robustness testing of live attenuated rubella vaccine potency assay using fractional factorial design of experiments.
    Kutle L; Pavlović N; Dorotić M; Zadro I; Kapustić M; Halassy B
    Vaccine; 2010 Jul; 28(33):5497-502. PubMed ID: 20472023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose response studies with Wistar RA 27/3 strain live attenuated rubella vaccine.
    Zealley H; Morrison AM; Freestone DS
    J Biol Stand; 1974 Apr; 2(2):111-9. PubMed ID: 4459391
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical trials with Cendehill strain attenuated rubella virus vaccine.
    Cherry JD; Horvath FL; Comerci GD; Rolfe UT; Bobinski JE; Hirschfeld JA; Shepard KS; Bruce HL
    Antimicrob Agents Chemother (Bethesda); 1969; 9():357-63. PubMed ID: 4918998
    [No Abstract]   [Full Text] [Related]  

  • 57. [Vaccination with live, non-virulent Trypanosoma cruzi vaccine in man. A 5-year follow up study the 1st 2 cases].
    Menezes H
    AMB Rev Assoc Med Bras; 1976 Jul; 22(7):252-2. PubMed ID: 790483
    [No Abstract]   [Full Text] [Related]  

  • 58. Diffuse myelitis associated with rubella vaccination.
    Holt S; Hudgins D; Krishnan KR; Critchley EM
    Br Med J; 1976 Oct; 2(6043):1037-8. PubMed ID: 990751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Production of vaccines with special reference to rubella vaccine RA 27-3 strain in WI 38 cells.
    Beale AJ
    Adv Exp Med Biol; 1972; 31(0):179-86. PubMed ID: 4671959
    [No Abstract]   [Full Text] [Related]  

  • 60. Serological follow-up after rubella immunisation.
    Ehrengut W; Lennartz H
    Br Med J; 1977 Aug; 2(6083):389. PubMed ID: 890315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.